Targeting the MEK5-ERK5-MEF2B pathway decreased TGF-β-mediated induction of EMT, as indicated by a phenotypic switch from epithelial to mesenchymal, cell migration, and lung metastases in breast cancer [64]. Here, MAP2K5 is linked to breast cancer.